About this trial
Numerous studies have demonstrated the significant contribution of S100B blood level measurement in the management of minor to moderate traumatic brain injuries, notably by reducing the number of cranial computed tomography (CT) scans by at least one-third. However, physiological blood concentrations of the S100B protein may be higher in individuals with a Black phenotype compared to those with Asian or, in particular, Caucasian phenotypes. Assessing S100B protein levels in healthy individuals will help confirm the variability of its physiological concentration according to skin phenotype.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Hospital staff of the University Hospital of Guadeloupe or the Hospital of Basse-Terre
Age between 18 and 65 years
Individuals willing to specify their ethnic origin and skin phototype
Individuals affiliated with or beneficiaries of a social security scheme
Disqualifiers
Individuals on anticoagulant therapy
Individuals with a personal history of neurological disease
Individuals with a personal history of melanoma
Refusal to participate
Trial population
Hospital staff of the University Hospital of Guadeloupe or the Basse-Terre Hospital
Trial design
Other
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
S100B and ethnicity
Level of S100B protein expressed in μg / L, which will be compared according to 3 groups: Afro-Caribbean, Indo-Caribbean and Caucasian.
Secondary outcomes
S100B and phototypes
Level of S100B protein expressed in μg / L studied according to the 6 phototypes of Fitzpatrick classification.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.